Ambroxol in Disease Modification in Parkinson Disease
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability and pharmacodynamics of ambroxol in
participants with Parkinson Disease. Participants will administer ambroxol at five dose
levels and will undergo clinical assessments, lumbar punctures, venepuncture, biomarker blood
analysis and cognitive assessment throughout the course of the study.
Phase:
Phase 2
Details
Lead Sponsor:
University College, London
Collaborators:
Cure Parkinson's Trust PRO.MED.CS Praha a.s - Czech Republic The Cure Parkinson's Trust